<b>Background</b>: Hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC) presents a persistent risk of relapse, even beyond 5 years, driving the need for adjuvant intensification strategies. Here, ERBB2 is linked to breast carcinoma.